Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 1/20 | 0.67 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.66 |
| ▸ | PKN1 | Q16512 | 3/20 | 0.66 |
| ▸ | PAK4 | O96013 | 2/20 | 0.66 |
| ▸ | CDK4 | P11802 | 8/20 | 0.61 |
| ▸ | CCND1 | P24385 | 8/20 | 0.61 |
| ▸ | CCND2 | P30279 | 7/20 | 0.61 |
| ▸ | CCND3 | P30281 | 7/20 | 0.61 |
| ▸ | PAK3 | O75914 | 2/20 | 0.59 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.53 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.53 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.53 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.51 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13553554 | 0.94 | WEE1 (0.70) | WEE1PAK1PKN1PAK4CDK4 | |
| SCHEMBL13553551 | 0.89 | WEE1 (0.64) | WEE1PAK1PKN1PAK4CDK4 | |
| SCHEMBL13553546 | 0.88 | WEE1 (0.65) | WEE1PAK1PKN1PAK4CDK4 | |
| SCHEMBL13553552 | 0.86 | WEE1 (0.64) | WEE1PAK1PKN1PAK4CDK4 | |
| SCHEMBL13553610 | 0.85 | PAK1 (0.69) | WEE1PAK1PKN1PAK4CDK4 | |
| SCHEMBL10192790 | 0.84 | WEE1 (0.77) | WEE1PAK1PKN1PAK4CDK4 | |
| SCHEMBL13553649 | 0.84 | WEE1 (0.62) | WEE1PAK1PKN1PAK4CDK4 | |
| SCHEMBL15030375 | 0.84 | WEE1 (0.71) | WEE1PAK1PKN1PAK4CDK4 | |
| SCHEMBL13553557 | 0.83 | WEE1 (0.70) | WEE1PAK1PKN1PAK4CDK4 | |
| SCHEMBL13553470 | 0.83 | PAK1 (0.81) | WEE1PAK1PKN1PAK4CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8372970-B2 | 8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372970-B2 | 8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120270866-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270866-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS INC. (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270866-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK5 | WEE1 850/4885PAK1 5/4885PKN1 528/4885 |
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK5 | WEE1 850/4885PAK1 5/4885PKN1 528/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | WEE1 545/4885PAK1 4/4885PKN1 326/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | WEE1 368/4885PAK1 2/4885PKN1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.